TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine

Overview

Journal Curr Pain Headache Rep

Date 2015 Mar 11

PMID 25754596

Citations 17

Authors

Sarah Walter

Marcelo E Bigal

Affiliations

Soon will be listed here.

Abstract

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide whose involvement in migraine pathophysiology is well established. Originally migraine was believed to be a disease of the vasculature, but research has highlighted this to be a disease of the brain with CGRP playing an important role. While targeting CGRP using small molecule antagonists against the receptor has been effective, long-term use of these agents has not been possible due to safety concerns and/or formulation challenges. Recent advances in therapeutic antibodies have opened up new possibilities for treatment of migraine. TEV-48125 is one of four monoclonal antibodies targeting CGRP or its receptors, currently in development for the preventive treatment of migraine. This article discusses the in vitro and in vivo pharmacology of TEV-48125 as well as highlighting its safety profile through the six Phase 1 studies that have been conducted. Finally, the current state of development and future studies for TEV-48125 will be reviewed.

Citing Articles

Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I.

Melhado E, Santos P, Kaup A, Costa A, Roesler C, Piovesan E Arq Neuropsiquiatr. 2022; 80(8):845-861.

PMID: 36252594 PMC: 9703891. DOI: 10.1055/s-0042-1756441.

Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.

McAllister P, Cohen J, Ramirez Campos V, Ning X, Janka L, Barash S J Headache Pain. 2022; 23(1):112.

PMID: 36038833 PMC: 9422163. DOI: 10.1186/s10194-022-01438-4.

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States.

Krasenbaum L, Pedarla V, Thompson S, Tangirala K, Cohen J, Driessen M J Headache Pain. 2022; 23(1):54.

PMID: 35508970 PMC: 9066733. DOI: 10.1186/s10194-022-01413-z.

Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials.

Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z Naunyn Schmiedebergs Arch Pharmacol. 2020; 394(4):819-828.

PMID: 33136176 DOI: 10.1007/s00210-020-02009-7.

No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.

Blumenfeld A, Stevanovic D, Ortega M, Cohen J, Seminerio M, Yang R Headache. 2020; 60(10):2431-2443.

PMID: 33009665 PMC: 7756709. DOI: 10.1111/head.13994.

References

Bigal M, Walter S, Rapoport A . Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013; 53(8):1230-44. DOI: 10.1111/head.12179. View

Bigal M, Walter S, Bronson M, Alibhoy A, Escandon R . Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia. 2014; 34(12):968-76. DOI: 10.1177/0333102414527646. View

Ho T, Ferrari M, Dodick D, Galet V, Kost J, Fan X . Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372(9656):2115-23. DOI: 10.1016/S0140-6736(08)61626-8. View

Bigal M, Escandon R, Bronson M, Walter S, Sudworth M, Huggins J . Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013; 34(7):483-92. DOI: 10.1177/0333102413517775. View

Ho T, Edvinsson L, Goadsby P . CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010; 6(10):573-82. DOI: 10.1038/nrneurol.2010.127. View

Bigal M, Walter S, Rapoport A . The vasodilatory activity of CGRP: a response. Headache. 2014; 54(4):748-9. DOI: 10.1111/head.12316. View

Eftekhari S, Edvinsson L . Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010; 3(6):369-78. PMC: 3002638. DOI: 10.1177/1756285610388343. View

Goadsby P . Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era?. Neurology. 2008; 70(16):1300-1. DOI: 10.1212/01.wnl.0000309214.25038.fd. View

Chan K, Edvinsson L, Eftekhari S, Kimblad P, Kane S, Lynch J . Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010; 334(3):746-52. DOI: 10.1124/jpet.110.165993. View

10.

Raddant A, Russo A . Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011; 13:e36. PMC: 3383830. DOI: 10.1017/S1462399411002067. View

11.

Schutz B, Mauer D, Salmon A, Changeux J, Zimmer A . Analysis of the cellular expression pattern of beta-CGRP in alpha-CGRP-deficient mice. J Comp Neurol. 2004; 476(1):32-43. DOI: 10.1002/cne.20211. View

12.

Van Der Schueren B, Blanchard R, Murphy M, Palcza J, De Lepeleire I, Van Hecken A . The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011; 71(5):708-17. PMC: 3093076. DOI: 10.1111/j.1365-2125.2010.03869.x. View

13.

Chaitman B, Ho A, Behm M, Rowe J, Palcza J, Laethem T . A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012; 91(3):459-66. DOI: 10.1038/clpt.2011.246. View

14.

Lynch J, Shen Y, Pittman T, Anderson K, Koblan K, Gould R . Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009; 623(1-3):96-102. DOI: 10.1016/j.ejphar.2009.09.018. View

15.

Silberstein S . Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2012; 93(1):78-85. DOI: 10.1038/clpt.2012.198. View

16.

Ho T, Connor K, Zhang Y, Pearlman E, Koppenhaver J, Fan X . Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014; 83(11):958-66. DOI: 10.1212/WNL.0000000000000771. View

17.

Thalakoti S, Patil V, Damodaram S, Vause C, Langford L, Freeman S . Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 2007; 47(7):1008-23. PMC: 2268711. DOI: 10.1111/j.1526-4610.2007.00854.x. View

18.

Silberstein S, Edvinsson L . Is CGRP a marker for chronic migraine?. Neurology. 2013; 81(14):1184-5. DOI: 10.1212/WNL.0b013e3182a6cc33. View

19.

van Rossum D, Hanisch U, Quirion R . Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997; 21(5):649-78. DOI: 10.1016/s0149-7634(96)00023-1. View

20.

Hewitt D, Aurora S, Dodick D, Goadsby P, Ge Y, Bachman R . Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31(6):712-22. DOI: 10.1177/0333102411398399. View